Please login to the form below
Lidoderm
This page shows the latest Lidoderm news and features for those working in and with pharma, biotech and healthcare.
Endo builds pain management business
Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine.
Latest news
-
Endo agrees $1.6bn deal to buy Paladin Labs
generic competition to Endo's Lidoderm (lidocaine) patch for post-shingles pain - and earnings per share (EPS) of $1.34, up from $1.28 a year earlier. ... Looking at the performance of Lidoderm, which fell 37 per cent, De Silva said that "prescription
-
Global survey shows neuropathic pain under-diagnosed and under-served
Lidoderm is licensed to Endo for sale in the US and Versatis is licensed to Gruenenthal for the UK. ... For Endo in the US, Lidoderm racked up sales of USD 419 million in FY05.
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Amgen developed a portfolio of supportive cancer care drugs including Epogen, Neupogen and Aranesp, and Endo Pharmaceuticals developed a pipeline of pain products that includes Lidoderm, Percocet and Opana.
-
Pharma deals during August 2013
The deal provides some protection for Endo's top-selling Lidoderm which accounted for 31 per cent of 2012 sales ($947.7m).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
